KAZIA THERAPEUTICS LTD
No SEC Form 4 filings for $KZIA in the last 30 days.
See all $KZIA insider activity →Guggenheim initiated coverage of Kazia Therapeutics with a Buy rating and $35 price target, implying 344.2% upside from the Oct 20 close. The analyst highlights strong clinical data for Paxalisib in treating metastatic triple-negative breast cancer and its unique mechanism of action.
Leerink Partners initiated coverage of Kazia Therapeutics with an Outperform rating and $30 price target, implying 282.2% upside from the Oct 19 close. The analyst highlights strong clinical data for Paxalisib in TNBC and GBM, and potential in HR+ breast cancer.
Kazia Therapeutics (KZIA) announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders. The milestone triggers a $2 million payment to Kazia, with potential for up to $17 million more. Paxalisib is being developed for intractable epilepsy associated with FCD T2 and TSC, with Kazia retaining oncology focus.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning KZIA (KAZIA THERAPEUTICS LTD). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent KZIA coverage spans technology, corporate actions and financial news.
Positive trial data and a new buy rating are likely to drive buying pressure.
Analyst upgrade and aggressive price target suggest strong upside potential.
The milestone payment and trial initiation provide near‑term upside potential for Kazia as it expands paxalisib beyond oncology.
Initiation of the trial may boost KZIA's pipeline credibility and attract investor interest.
Financing strengthens cash runway but introduces dilution; early‑stage trial limits near‑term upside.
AlphAI scores every news story that mentions KZIA with an AI model for sentiment and relevance, and aggregates insider trades from KAZIA THERAPEUTICS LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim initiated coverage of Kazia Therapeutics with a Buy rating and $35 price target, implying 344.2% upside from the Oct 20 close. The analyst highlights strong clinical data for Paxalisib in treating metastatic triple-negative breast cancer and its unique mechanism of action.
1 min readLeerink Partners initiated coverage of Kazia Therapeutics with an Outperform rating and $30 price target, implying 282.2% upside from the Oct 19 close. The analyst highlights strong clinical data for Paxalisib in TNBC and GBM, and potential in HR+ breast cancer.
1 min readKazia Therapeutics (KZIA) announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders. The milestone triggers a $2 million payment to Kazia, with potential for up to $17 million more. Paxalisib is being developed for intractable epilepsy associated with FCD T2 and TSC, with Kazia retaining oncology focus.
2 min readKazia Therapeutics (NASDAQ: KZIA) announced the first patient has been dosed in a Phase 2 study (PNOC035) evaluating paxalisib plus gemcitabine for recurrent pediatric AT/RT brain cancer. The study, conducted by the Pediatric Neuro-Oncology Consortium, aims to address a condition with no approved therapies. Preclinical data showed a significant survival increase, supporting the trial's rationale. Paxalisib has received FDA orphan drug and rare pediatric disease designations for AT/RT.
2 min readKazia Therapeutics (KZIA) raised $40M in a public offering, with potential for $120M including warrant exercises. The company is expanding a breast cancer study for paxalisib, targeting enrollment by 2027. Proceeds support clinical trials and working capital, but preclinical evidence is still early.
3 min readKazia Therapeutics (KZIA) reported paxalisib reduced tumor burden by 52% in a colorectal cancer model. The company plans a Phase 2 trial in 2027, evaluating paxalisib alone and with immunotherapy. Kazia is developing biomarkers and has filed a patent for colorectal cancer applications.
1 min readBTIG raised its price target for Kazia Therapeutics (NASDAQ:KZIA) to $40 from $34, citing positive trial data for paxalisib in metastatic triple-negative breast cancer. The stock has surged nearly 100% year-to-date to $12.71. Kazia also announced a $40 million public offering. BTIG noted the data showed an 83% overall response rate and no serious adverse events.
2 min readKazia Therapeutics reported preclinical data showing its drug paxalisib reduced tumor burden in MSS/pMMR colorectal cancer by 52%. Combining it with pembrolizumab further reduced tumor volume by 50%. The company plans a Phase 2 trial in 2027, with safety and survival as key endpoints. Paxalisib is well-tolerated and has shown potential in overcoming immunotherapy resistance.
2 min readKazia Therapeutics (NASDAQ: KZIA) is expanding its clinical trial for paxalisib to include HR+/HER2- breast cancer, following preclinical data showing strong antitumor activity and safety. The trial will evaluate paxalisib combined with standard therapies, with enrollment expected by 2027. The company filed a related patent and aims to present additional data later this year.
2 min readKazia Therapeutics (NASDAQ: KZIA) closed an oversubscribed public offering, raising $40 million upfront. The offering includes milestone-linked warrants, potentially adding $80 million if exercised, totaling $120 million. Proceeds will fund clinical trials for paxalisib and general corporate purposes. The company will host a corporate update call on September 1, 2026.
2 min read
